Details for New Drug Application (NDA): 061859
✉ Email this page to a colleague
NDA 061859 describes ANSPOR, which is a drug marketed by Glaxosmithkline and is included in two NDAs. Additional details are available on the ANSPOR profile page.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Summary for 061859
| Tradename: | ANSPOR |
| Applicant: | Glaxosmithkline |
| Ingredient: | cephradine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061859
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 250MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 500MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
